Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

109.43USD
23 Sep 2016
Change (% chg)

-- (--)
Prev Close
$109.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,254,409
52-wk High
$128.39
52-wk Low
$93.05

Select another date:

Fri, Sep 16 2016

BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial

* Celgene Corp -Oral Ozanimod efficacy and safety results at 2 years from Phase 2 RADIANCE trial of patients with relapsing multiple Sclerosis presented at 32nd Ectrims

BRIEF-Sutro Biopharma receives 2 milestone payments from Celgene

* Sutro Biopharma Inc says financial terms of milestones are not being disclosed.

BRIEF-Agios Pharma says Celgene expects to submit NDA to U.S. FDA for enasidenib

* Celgene corporation expects to submit a new drug application to U.S. FDA for Enasidenib (ag-221)

BRIEF-Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals

* Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing Source text: (http://bit.ly/2bBcQ6P) Further company coverage:

BRIEF-Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources

* Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Sales of flagship drug Revlimid drive Celgene profit; forecast raised

NEW YORK Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares.

UPDATE 3-Sales of flagship drug Revlimid drive Celgene profit; forecast raised

NEW YORK, July 28 Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares.

Celgene revenue rises on higher demand for flagship drug Revlimid

July 28 U.S. biotechnology company Celgene Corp reported a 21 percent jump in quarterly revenue, driven by demand for its key multiple myeloma drug, Revlimid.

BRIEF-Celgene reports Q2 GAAP earnings per share $0.75

* Celgene reports second quarter 2016 operating and financial results

Celgene drug fails to extend survival in lymphoma study

Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.

Select another date: